Is NADH Effective in the Treatment of Parkinson’s Disease?

@article{Swerdlow1998IsNE,
  title={Is NADH Effective in the Treatment of Parkinson’s Disease?},
  author={R. Swerdlow},
  journal={Drugs & Aging},
  year={1998},
  volume={13},
  pages={263-268}
}
  • R. Swerdlow
  • Published 1998
  • Medicine
  • Drugs & Aging
  • Most Parkinson’s disease (PD) treatments palliate symptoms by increasing nigrostriatal dopaminergic tone. A unique strategy for accomplishing this pharmacological end-point proposes using reduced nicotinamide adenine dinucleotide (NADH) to boost endogenous dopamine production, since NADH indirectly supplies reducing equivalents to the rate-limiting, tyrosine hydroxylase-catalysed step of dopamine synthesis. Support for using NADH in PD treatment includes claims that NADH stimulates tyrosine… CONTINUE READING
    15 Citations
    A synopsis on the role of tyrosine hydroxylase in Parkinson's disease.
    • 69
    Effects of NADH on dopamine release in rat striatum
    • 7
    • PDF
    No evidence for cognitive improvement from oral nicotinamide adenine dinucleotide (NADH) in dementia
    • 27
    • PDF
    Treating neurodegeneration by modifying mitochondria: potential solutions to a "complex" problem.
    • R. Swerdlow
    • Biology, Medicine
    • Antioxidants & redox signaling
    • 2007
    • 76
    Nicotinamide Improves Aspects of Healthspan, but Not Lifespan, in Mice.
    • 80
    • PDF
    NAD+ and NADH in brain functions, brain diseases and brain aging.
    • W. Ying
    • Medicine, Biology
    • Frontiers in bioscience : a journal and virtual library
    • 2007
    • 74
    • PDF

    References

    SHOWING 1-10 OF 28 REFERENCES
    Treatment of Parkinson's disease with NADH
    • 16
    MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE
    • 1,313
    Abnormalities of the electron transport chain in idiopathic parkinson's disease
    • 1,040
    Oxidative stress and the pathogenesis of Parkinson's disease
    • 910
    The coenzyme nicotinamide adenine dinucleotide (NADH) improves the disability of Parkinsonian patients
    • 18
    • Highly Influential
    • PDF
    CNS Modulation of adrenal tyrosine hydroxylase in Parkinson's disease and metabolic encephalopathies.
    • 59
    Mitochondrial oxidative phosphorylation defects in parkinson's disease
    • 328